Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07319767 | Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors | completed | — | 120 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT00116454 | Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis(Lipiocis) | completed | Phase 3 | 73 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Apr 3, 2026 |
| clinicaltrials |
| NCT02077881 | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04877821 | The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC(NeoSACT) | completed | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03798626 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | completed | Phase 1 | 167 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 1, 2026 | clinicaltrials |
| NCT05807776 | Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. | completed | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06133465 | Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management | completed | — | 1,063 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02435953 | TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma(TORCH) | completed | Phase 3 | 241 | Ming ZhaoOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02555748 | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma(SUP-R) | completed | Phase 4 | 47 | Institut Claudius RegaudOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03947151 | Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer(DEGASTIM) | completed | Phase 2 | 8 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04620538 | Volatile Organic Compounds for the Assessment of Liver Disease(VOCAL) | completed | — | 56 | Imperial College LondonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03586297 | Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer | completed | — | 49 | Hackensack Meridian HealthOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06133647 | Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System | completed | — | 8 | Methodist Health SystemOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06311396 | Development of a Neuronal Microscope | completed | N/A | 30 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies(HERKULES-3) | completed | Phase 1 / Phase 2 | 101 | Erasca, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04903548 | Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres | completed | — | 1 | Methodist Health SystemOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03753659 | IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 30 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04539938 | A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer(HER2CLIMB-04) | completed | Phase 2 | 70 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03709446 | Leflunomide in Previously Treated Metastatic Triple Negative Cancers | completed | Phase 1 / Phase 2 | 17 | Joseph SparanoOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04720716 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | completed | Phase 3 | 344 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04960059 | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | completed | — | 24 | The Christie NHS Foundation TrustOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT06354387 | Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 | completed | Phase 1 | 5 | China Medical University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07004426 | Symptomatic and Incidental RCC Detection(KIDCaD) | completed | — | 1,000 | Charles University, Czech RepublicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483242 | Individualized Surgical Guidance in HCC-BDTT | completed | — | 151 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT05340413 | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.(RADIOLA) | completed | Phase 2 | 65 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT01165346 | Stereotaxic Irradiation of Hepatocellular Carcinoma(CKNO-HEP) | completed | Phase 2 | 44 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03151213 | Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver(pregabalin) | completed | Phase 4 | 70 | Sherief Abd-ElsalamOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07193316 | Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis(SEEK) | completed | — | 38 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03142334 | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | completed | Phase 3 | 994 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05665348 | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy(TRIPLET) | completed | Phase 2 / Phase 3 | 229 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02047474 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 46 | Yale UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07453433 | Submucosal Pressure Ejection Endoscopic Dissection for Early Gastric Cancer: a Retrospective Cohort Study | completed | — | 548 | Shanghai East HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04288687 | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | completed | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05432492 | A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 40 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07449065 | CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC | completed | — | 324 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT01409200 | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | completed | Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03686488 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02184416 | Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting(ADONIS) | completed | — | 554 | PfizerINDUSTRY | 8 | Feb 27, 2026 | clinicaltrials |
| NCT07436416 | Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer(EXO-RENAL2) | completed | N/A | 91 | Institute of Oncology LjubljanaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04945720 | Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04469556 | Pancreatic Adenocarcinoma Signature Stratification for Treatment(PASS-01) | completed | Phase 2 | 150 | University Health Network, TorontoOTHER | 2 | Feb 20, 2026 | clinicaltrials |
| NCT06235099 | Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer(Solar-Recur) | completed | Phase 3 | 235 | Curium US LLCINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07407257 | SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors | completed | N/A | 65 | Institute of Oncology LjubljanaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2026source: clinicaltrials